Recro to Present at H.C. Wainwright Global Life Science Conference

Recro Pharma (NASD: REPH) announced its CEO David Enloe will present at the H.C.

Rhea-AI Summary

Recro Pharma (NASD: REPH) announced its CEO David Enloe will present at the H.C. Wainwright Global Life Science Conference on March 9-10, 2021. The event will be held virtually, allowing Recro to showcase its capabilities as a contract development and manufacturing organization (CDMO). Recro specializes in addressing complex formulation challenges in the pharmaceutical industry, with facilities located in Gainesville, Georgia, totaling 120,000 square feet.

Argus Session date unavailable

-5.28% session move Open Argus

Details

News Market Reaction – REPH

The recorded move for REPH in the trading session of this news was -5.28%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MALVERN, Pa., March 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright Global Life Science Conference. The conference, which will take place March 9-10, 2021, is being conducted with a virtual format.

Details for the corporate presentation are as follows:

• H.C. Wainwright Global Life Science Conference
  Details: Recro management will deliver a corporate presentation and participate in 1-on-1 meetings
  Conference dates: March 9-10, 2021
  Format: Virtual conference

About Recro
Recro (NASD: REPH) is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

In addition to our experience in handling DEA controlled substances and developing and manufacturing modified release oral solid dosage forms, Recro has the expertise to deliver on our clients’ pharmaceutical development and manufacturing projects, regardless of complexity level. We do all of this in our best-in-class facilities, which total 120,000 square feet, in Gainesville, Georgia.

For more information about Recro’s CDMO solutions, visit recrocdmo.com.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the purpose of Recro Pharma's participation in the H.C. Wainwright Global Life Science Conference?

Recro Pharma's CEO David Enloe will deliver a corporate presentation and engage in 1-on-1 meetings during the H.C. Wainwright Global Life Science Conference.

When is the H.C. Wainwright Global Life Science Conference taking place?

The H.C. Wainwright Global Life Science Conference is scheduled for March 9-10, 2021.

What does Recro Pharma specialize in as a CDMO?

Recro Pharma specializes in solving complex formulation and manufacturing challenges for oral solid dose drug products.

Where is Recro Pharma's manufacturing facility located?

Recro Pharma's manufacturing facility is located in Gainesville, Georgia, covering 120,000 square feet.

What are the capabilities of Recro Pharma as a contract development and manufacturing organization?

Recro offers services from early feasibility to commercial manufacturing, including regulatory support and packaging logistics.